Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin Prophylaxis for Preeclampsia
ChiCTR2600128886Phase 4Not yet recruiting
- Sponsor
- Guangdong Women and Children Hospital
- Start
- Jul 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aspirin in preeclampsia, eclampsia, HELLP syndrome (HELLP) and 1 more (2 arms), sponsored by Guangdong Women and Children Hospital. Primary endpoint: Incidence of preeclampsia/eclampsia at 37 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
aspirin
03
Conditions
preeclampsiaeclampsiaHELLP syndrome (HELLP)pregnancy-induced hypertension (PIH)
Beyond the preview
Go deeper on ChiCTR2600128886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128886.